Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN^®, for the treatment of gastric cancers.

"Oncolytics has assembled a portfolio of six indications where we have been granted Orphan Drug Designation by the FDA," said Dr. Brad Thompson, President and CEO of Oncolytics. "We expect this will provide us with greater flexibility in the future development of REOLYSIN^® for these difficult to treat cancers."